Mirtazapina Sandoz (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Sandoz, is a tetracyclic antidepressant (NaSSA) presented as an oral dosage form for oral use. It is indicated for the treatment of major depressive disorder in adult patients.

GNH USA supplies Mirtazapina Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine acts within the central nervous system to alleviate depressive symptoms in the mood‑disorder therapeutic area.

- Major depressive disorder: reduces depressive symptoms and improves mood in adult patients.

Mirtazapine may cause a range of adverse reactions.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Peripheral edema

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Seizures - Severe hypotension - Suicidal thoughts or behavior - Hepatic dysfunction - Blood dyscrasias such as thrombocytopenia

Before initiating therapy, consider the following safety measures.

- Hepatic function assessment: evaluate liver enzymes in patients with liver disease. - Suicidal ideation monitoring: watch for emergence or worsening of suicidal thoughts. - Cardiovascular caution: use carefully in patients with hypotension or cardiac disease. - Renal impairment adjustment: dose may need modification in severe renal dysfunction. - Discontinuation: avoid abrupt cessation to reduce withdrawal symptoms. - Store at room temperature: keep in the original pack, protect from moisture.

Mirtazapine can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - Serotonergic antidepressants (e.g., SSRIs, SNRIs): potential serotonin syndrome. - Central nervous system depressants (e.g., benzodiazepines, alcohol): additive sedation.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma levels. - Antihypertensive agents: possible enhanced hypotensive effect. - Anticholinergic drugs: may increase anticholinergic burden.